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REVIEW ARTICLE

Recurrent Encephalopathy: NAGS (NAcetylglutamate Synthase) Deficiency in
Adults
A. Cartagena, A.N. Prasad, C.A. Rupar, M. Strong, M. Tuchman, N. Ah Mew,
C. Prasad

ABSTRACT: N-acetyl-glutamate synthase (NAGS) deficiency is a rare autosomal recessive urea cycle
disorder (UCD) that uncommonly presents in adulthood. Adult presentations of UCDs include;
confusional episodes, neuropsychiatric symptoms and encephalopathy. To date, there have been no
detailed neurological descriptions of an adult onset presentation of NAGS deficiency. In this review we
examine the clinical presentation and management of UCDs with an emphasis on NAGS deficiency. An
illustrative case is provided. Plasma ammonia levels should be measured in all adult patients with
unexplained encephalopathy, as treatment can be potentially life-saving. Availability of Ncarbamylglutamate (NCG; carglumic acid) has made protein restriction largely unnecessary in treatment
regimens currently employed. Genetic counselling remains an essential component of management of
NAGS.
RÉSUMÉ: Encéphalopathie récurrente : le déficit en NAGS (N-acétylglutamate synthase) chez l'adulte. Le
déficit en N-acétyl-glutamate synthase (NAGS) est un désordre rare du cycle de l'urée (DCU) transmis de façon
autosomique récessive qui survient rarement à l'âge adulte. Le mode de présentation des DCU chez l'adulte inclut
des épisodes de confusion, des symptômes neuropsychiatriques et une encéphalopathie. À ce jour, il n'existe pas de
description neurologique détaillée du mode de présentation du déficit en NAGS chez l'adulte. Dans cette revue, nous
examinons le mode de présentation clinique et la prise en charge des DCU, particulièrement le déficit en NAGS, ainsi
qu'une observation clinique. Les niveaux plasmatiques d'ammoniac devraient être mesurés chez tous les patients
adultes présentant une encéphalopathie inexpliquée, étant donné que le traitement de cette pathologie peut leur
sauver la vie. Depuis que le N-carbamylglutamate (NCG; acide carglumique) est disponible, il n'est plus nécessaire
de restreindre l'apport en protéines chez ces patients. Le conseil génétique demeure une composante essentielle de la
prise en charge du déficit en NAGS.

Can J Neurol Sci. 2013; 40: 3-9

In humans and other mammals nitrogen is produced by the
catabolism of proteins and excreted as urea via the kidneys
through the process of the urea cycle1 (Figure 1). The urea cycle
which is active primarily in the liver converts waste nitrogen into
ammonium. Deficiencies of enzymes in the urea cycle may
result in the accumulation of ammonium. Urea cycle disorders
may present from infancy to adulthood.

deficiency are inherited in an autosomal recessive manner.
Enzymes located in the mitochondria are CPSI, NAGS, and
OTC; these can therefore be affected by other mitchondrial
diseases or perturbations. The incidence of urea cycle disorder
(UCDs) in the United States is approximately 1 in 82004.
Prenatal testing based on mutation analysis is available for all six
conditions5-7.

The urea cycle consists of six enzymes and two mitochondrial membrane transporters (Figure 1): N-acetyl glutamate
synthase (NAGS), carbamyl phosphate synthetase I (CPSI),
ornithine transcarbamylase (OTC), argininosuccinate synthetase
(ASS), argininosuccinate lyase (ASL), arginase, the aspartate
transporter (citrin), and the ornithine transporter1-3. An
interruption in any step of the urea cycle may cause a build-up of
ammonium which is neurotoxic and if untreated may result in
coma and death. All disorders except for X-linked OTC
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Figure 1: Simplified version of urea cycle depicted. The urea cycle
converts protein into urea which is excreted by the kidneys. There are six
enzymes involved: N-acetylglutamate synthase (NAGS), carbamylphosphate-synthetase-I (CPSI), ornithine transcarbamylase (OTC),
argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL),
arginase (ARG1). Further abbreviations: adenosine triphosphate (ATP),
adenosine diphosphate (ADP. Redrawn with permission from: Lee B.
Urea cycle disorders: Management. In: UpToDate, Basow, DS (Ed),
UpToDate, Waltham, MA 2012. Copyright © 2012 UpToDate, Inc. For
more information visit www.uptodate.com.

Clinical presentation of UCDs

The typical presentation for a urea cycle disorder occurs in
the first few days of life. The infant may present with
gastrointestinal symptoms such as vomiting occurring after
feeding (protein load). Neurological symptoms such as lethargy,
seizures and coma can follow quickly, a presentation identical to
that of an infant with sepsis. A non-diagnostic work-up for sepsis
should raise the clinical suspicion for an inborn error of
metabolism. A common sign is hyperventilation and respiratory
alkalosis as ammonium is a central nervous system (CNS)
stimulant. Hyperventilation is thought to result from cerebral
edema caused by the build up of ammonium;8 however
hyperventilation can also be seen without evidence of cerebral
edema. Neonates who present in the first few days of life do so
as a result of the catabolic stress of labour and delivery and low
fluid intake in the immediate post natal period.
Patients who have partial enzyme deficiencies, such as
female carriers (X-linked OTC deficiency) will often have a
delayed presentation despite a lifelong history of chronic cyclical
nausea and vomiting, and possibly a seizure disorder or a
psychiatric illness9. There may also be developmental delay.
Many patients self-select a low protein diet. In all groups of
patients hyperammonemic crises may occur with increased
catabolic stress caused by infection, starvation, surgery or
trauma.

Figure 2: Recommended laboratory studies for a patient with a
suspected inborn error of metabolism. Modified from Burton B. Inborn
errors of Metabolism in Infancy: A Guide to Diagnosis. Pediatrics
1998;102(6):e69-e77.

serum lactate, serum glucose and cerebrospinal fluid (CSF)
analysis, (with hyperammonemia there can be cerebral edema so
CSF analysis should only be performed with caution) (Figure 2).
It is important to note that hyperammonemia may be chronic or
occur only during metabolic decompensation and therefore
investigations can be normal10. Electroencephalogram (EEG)
(Figure 3) and magnetic resonance (MR) imaging can be helpful
investigations. Fluid attenuated inversion recovery sequence
(FLAIR) on MR imaging has been suggested to identify white
matter tract abnormalities that can exist in UCDs11. Other
imaging techniques described to show abnormalities include
diffusion tensor imaging (DTI) and MR spectroscopy. If plasma
ammonia is elevated then metabolic indices such as plasma
amino acids, urine orotic acid and urine organic acids should be
measured. The importance of testing these metabolic indices is
to differentiate among the various UCDs (Figure 4). A genetics
and metabolic consultation is useful to proceed with further

Approach to a patient with a suspected UCD

The approach to a patient considered to have a UCD includes
a comprehensive neurological assessment with particular
attention to family history and key clinical features such as
behavioural changes, protein aversion and gastrointestinal
symptoms. Investigations should first and foremost include an
ammonia level. Other key investigations include arterial pH,
4
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Figure 3: Electroencephalogram. Referential montage (common
average reference) shows diffuse background slowing (delta) with the
intermittent appearance of triphasic waves, with a bifrontal
predominance.
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Figure 4: Flow chart for the approach to hyperammonemia. Modified
from Burton B. Inborn errors of Metabolism in Infancy: A Guide to
Diagnosis. Pediatrics 1998;102(6):e69-e77., and Summar M. Current
strategies for the management of neonatal urea cycle disorders. J
Pediatr. 2001 Jan;138(1 Suppl):S30-9.

work up for molecular analysis or tissue enzyme analysis.
Patients suspected to be having a UCD should be managed in an
intensive care setting as this is a medical emergency. Cerebral
edema occurs early with severe hyperammonemia, and delays in
reducing the level of ammonia may lead to serious neurological
complications including death due to increased intracranial
pressure with herniation. Survival from a severe episode often
carries with it irreversible brain damage. Treatment should thus
not be delayed if a UCD is suspected.
Medical and metabolic management

In an emergent presentation, physiologic stabilization is most
important; adjunctive treatment may include intravenous fluids,
and possibly hemodialysis for ammonia removal. The mainstay
of ongoing management of NAGS deficiency, as with all UCDs
is maintenance of plasma ammonia levels in a normal range by
limiting protein intake, avoiding periods of catabolic stress, and
using nitrogen scavenger drugs to allow an alternate pathway
for the excretion of nitrogen precursors12,13 (e.g. sodium
phenylbutyrate). Recently, in NAGS deficiency, specific
treatment with carglumic acid, a structural analog of NAG has
been used as it has been shown to activate CPSI14-17 and restore
ureagenesis2,9. Patients receiving carglumic acid typically do not
require a protein restricted diet.
NAGS deficiency

N-acetylglutamate synthase (NAGS; MIM# 608300), one of
the three mitochondrial enzymes of the urea cycle, produces Nacetylglutamate (NAG) from glutamate and acetyl coenzyme A
(Acetyl CoA). N-acetylglutamate was first identified in the
1950’s and initially discovered as an intermediate in the argininebiosynthetic pathway of Escherichia coli. N-acetyl glutamate
synthase was later described as an essential allosteric cofactor of
Volume 40, No. 1 – January 2013
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mitochondrial carbamylphosphate synthetase I (CPSI), the first
enzyme of the urea cycle18. N-acetyl glutamate synthase is
primarily expressed in the liver and in the small intestine and its
product, NAG, is postulated to activate CPSI19. Hyperammonemia can result once CPSI is deprived of its co-factor
NAG.
The first case report of NAGS deficiency was published in
198120 and subsequently approximately 34 other cases of NAGS
deficiency have been reported with most patients presenting in
the neonatal period17. N-acetyl glutamate synthase deficiency is
the least common UCD and few late-onset neurological
presentations have been described2,20-22; the gene mutation maps
to chromosome 17q21.3119. There are 22 published mutations up
to date that have been described for NAGS3,23.
Deficiencies of NAGS activity can either be inherited
(mutation in NAGS gene) or acquired by a secondary inhibition
of NAGS activity in some conditions which cause short chain
fatty acid accumulation such as some organic acidemias and the
use of valproic acid.
A detailed summary of published cases of NAGS in the
literature is listed in the Table. Literature searches were done
using online data bases such as PUBMED, GENE REVIEWS
and OMIM. In total, 34 cases of confirmed NAGS deficiency
were identified. This mini review will help with the
understanding of the genetic aspects and key neurologic features
associated with UCDs and therefore prompt earlier diagnosis
and treatment. We discuss the unique presentation of an adultonset UCD. Our patient had a history of behavioural change and
confusion which is in keeping with a late-onset UCD. An adult
presentation of NAGS deficiency however is very rare. No
trigger was identified in our patient to account for his
hyperammonemic crises.
Illustrative Case

The patient was symptomatic in early childhood and
adulthood with symptoms of hyperammonemia in the setting of
a negative family history although no ammonia level was
checked until his hospitalization at age 38 years. A key clinical
feature was an almost 20 year history of fluctuating behavioural
changes associated with nausea and vomiting. A 38-year-old lefthanded dairy farmer was referred for acute confusion and bizarre
behavioural changes. His past medical history was notable for
similar episodes dating as far back as 18 years. There had been
no previous psychiatric or neurologic evaluation, however, a
normal cranial computed tomogram (CT) scan had been
reported. He was taken to the emergency room by his wife and
upon assessment he described ongoing nausea and vomiting as
well as headache. The patient had completed secondary school
and two years of college with no history of learning difficulties.
He was from a non-consanguineous Irish and Scottish
background with no relevant family history.
On examination vital signs were stable. There was
behavioural disinhibition and fluctuating drowsiness. A minimental status examination (MMSE) score was 23/30, (points lost
for five-minute recall, three-step command, and constructing
intersecting pentagons). Cranial nerve examination and power
testing was normal. There was mild spasticity on assessment of
muscle tone with brisk reflexes, sustained ankle clonus, and
down-going plantar reflexes. Coordination was impaired.
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At birth;
Ukn
40 years;
female

33 years;
female

4 days;
female

3 months;
male

Screened
at birth;
male

3

5

6

7

8

9

6
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3 days;
Ukn

3-4 days;
ukn
6 days;
Ukn

3 days;
Ukn

3 days;
female

16 hours;
male

3 days;
female
2 days;
female

4 days;
male

at birth;
male
4 years;
male

12 years
11
months;
female

13

14

16

17

18

19

21

22

24

23

20

15

12 years;
male

12

11

10

4 weeks;
female
9 years;
female
33 years;
male

Screened
at birth;
female

4

6 male

2

Age at
diagnosis;
Sex

1

Case

Ukn
No
Austrian/
Slovenian
No

Iranian Jewish/
First cousins

Distant
approximately 5
generations back
Hispanic/
No

Faroe Islands

No

German

Yes

Turkish

No

Turkish
Yes
German

Turkish
Yes

No

Ukn

No

White

Ukn

No

Ukn

Yes; first cousins

French

Yes; same village

Ukn

Ukn

Ukn

Ukn

First cousins

Turkish

Ukn

Background
Consanguinity

No

None

Yes; younger brother to case 21

Ukn
One of twin (other twin unaffected)

Yes; younger sibling case 19

No

Ukn

Ukn

Ukn

Ukn

Ukn

Ukn

Ukn

None

Yes; younger sister case 9

No

Older sister died of severe
hyperammonemia, no diagnosis made

Ukn

Ukn

Ukn

Ukn

Ukn

Yes; older sister died of severe
hyperammonemia (NAGS deficiency not
confirmed)

Ukn

Family History

vomiting, protein aversion, restlessness,
disorientation, aggression, hyperreflexia

irritability, vomiting, lethargy, protein refusal,
ataxia, worsened with VPA

coma

unresponsive, seizures

lethargy, anorexia, respiratory distress, coma,
seizures
lethargy, anorexia, vomiting, respiratory
distress and seizures

tachypnea, jitteriness, hypertonia, hypothermia,
coma

signs of cerebral edema

Ukn

Ukn

Ukn

Ukn

vomiting, decreased LOC with protein, EEG
showed left temporal lobe spikes

recurrent vomiting, irritability, lethargy, lateron headaches, hallucinations
lethargy, anorexia, vomiting, respiratory
distress and seizures
post-operative combativeness, confusion,
seizures

asymptomatic

muscular axial hypotonia, hyporeactivity,
hepatomegaly

hypotonia, drowsiness, tremor, and no suck

intermittent staring spells, nausea, recurrent
vomiting, lethargy, ataxia, migraine headaches,
eventually coma
episodic altered mental status with coma after
caesarean section. Psychomotor seizures

coma, seizures

vomiting, feeding intolerance, episodic
confusion
asymptomatic

Clinical findings

No

No

No

No

No

No

Yes

Yes

Ukn

Ukn

Ukn

Ukn

No

Yes

No

No

No

No

No

No

No

No

No

No

Death

221

229

1900

1300

978

1700

Ukn

942

Ukn

Ukn

Ukn

Ukn

350

621

978

256

208

113-367

182

138 - 4781

500

>1400

393

Peak
Ammonia*
Normal <50
mmol/L
500

1616

920

1732

2652

1710

1268

elevated

801

elevated

1710

elevated

1114

841

1150

Ukn

Ukn

Ukn, but 1961 on
subsequent
admission

Ukn

Gln on admission*
Normal 109-750
mmol/L

12

Ukn

ND

ND

ND

ND

Ukn

Ukn

Ukn

Ukn

21

Low

ND

normal

<4

19

13

Ukn

Ukn

Ukn

Ukn

Cit on
admission*
Normal 1050 mmol/L
Ukn

Table: Summary of findings in reported cases of confirmed N-acetylglutamate synthase (NAGS) deficiency

Partial NAGS deficiency
Liver biopsy: NAGS activity reduced 15%
control

Liver biopsy:
NAGS activity reduced 26% control

Initial liver biopsy inconclusive, later molecular
analysis confirmed homozygous NAGS gene
mutation
Homozygous NAGS gene mutation

Molecular studies: both homozygous for NAGS
gene mutation

Post-mortem liver tissue: reduced NAGS
Later parents found to be heterozygotes

Liver biopsy: reduced NAGS activity, NAGS
mutation confirmed using cultured fibroblasts
and DNA sequencing

NAGS deficiency on mutation analysis

Liver biopsy:
No NAGS activity; later
NAGS mutation found

NAGS deficiency on mutation analysis

Liver biopsy:
L-Arginine unable to activate NAGS and
normal CPS activity.
NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

Initially NAGS not assayed on liver biopsy
Later NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

NAGS deficiency on mutation analysis

Second liver biopsy: reduced NAGS activity,
later found to be homozygous for NAGS
mutation

NAGS deficiency on mutation analysis

Diagnosis by: enzyme analysis OR
molecular studies

Plecko et al. Eur J Pediatr.
1998;157(12):996-998.47
Haberle et al. Hum Mutat. 2003;21(6):593597.23

Forget et al. Acta Paediatr.
1999;88(12)1409-1411.46

Elpeleg et al. Ann Neurol. 2002;52(6):84589.45

Caldovic et al. Hum Genet 2003; 112:364–
368.43

Haberle et al. Human
Mutat.2003;21(6)593-597.23
Schmidt et al. Biochim Biophys Acta.
2005;1740:54-59.39
Haberle et al. J Inherit Metab Dis
2003;26(6):601-605.42
Haberle et al. Human
Mutat.2003;21(6)593-597.23
Caldovic et al. Hum Genet 2003; 112:364–
368.43
Takanashi J., et al. Am J Neuroradiol (in
press) 2002.44

Haberle et al. Human
Mutat.2003;21(6)593-597.23
Heckmann et al. Acta
Paediatr.2005;94(1):121-124.41
Haberle et al. Human
Mutat.2003;21(6)593-597.23
Haberle et al. Human
Mutat.2003;21(6)593-597.23

Belanger-Quintana et al. Eur J Pediatr.
2003;162(11)773.775.40

Caldovic et al. Hum Mutat.
2005;25(3):293-298.2

Caldovic et al. J Pediatr 2004;145:552554.18

Guffon et al. J Pediatr 2005;147:260-262.
Schmidt et al. Biochim Biophys Acta.
2005;1740:54-59.39

Guffon et al. J Pediatr 2005;147:260-262.38
Schmidt et al. Biochim Biophys Acta.
2005;1740:54-59.39

Grody et al. J Inherit Metab
Dis.1994;17(5):566-574.37
Caldovic et al.Human
Mutat.2007;28(8)754-759.3
Guffon et al. J Pediatr 2005;147:260-262.38
Schmidt et al. Biochim Biophys Acta.
2005;1740:54-59.39

Nordenstrom et al. J Inherit Metab Dis
2007; 30:400.36
Tuchman et al. Pediatr Res 2008;64(2):213217.22

Corne et al. Mol Genet Metab 2011;
102;275.34
Gessler et al. Eur J Pediatr 2010;169:197–
199.35
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Ukn (unknown), LOC (loss of consciousness), CPS (carbamoyl phosphate synthetase) mat. (maternal), EEG (electroencephalogram), VPA (valproic acid). Gln (Glutamine), Cit (Citrulline),
ND (Not Detectable)

NAGS deficiency on mutation analysis
15
1062
434
No
Episodic confusion, nausea and vomiting
None
Irish-Scottish
38; male

No

35

34

33

No

Bachmann et al. J Inherit Metab Dis.
1988;11(2):191-193.54
Bachmann et al. N Engl J Med. 1981 Feb
26;304(9):543.20 (INDEX CASE)
Schubiger et al. Eur J Pediatr. 1991
Mar;150(5):353-356.55
Liver biopsy: NAGS activity Not detectable
Ukn

ND

242
Died at
age 9

1020

711
Yes

poor feeding, vomiting, hypotonia, respiratory
alkalosis
hyperthermia, muscular hypertonia, respiratory
distress, abdominal distension
Ukn
No
Ukn

2 siblings died during neonatal period,
postmortem analysis from 2nd sibling
suggested ! ammonia

None

940

None; positive family history

Partial NAGS deficiency
Liver biopsy: NAGS activity reduced to 33% of
control
Liver biopsy: NAGS activity Not detectable
ND

Low
Elevated

549
241
Yes
coma, hypotonia, hyperreflexia, hepatomegaly,
EEG showed triphasic waves

185
No
diarrhoea, irritability, tachypnea, hypertonia

26 days;
male
13
months;
female
6 days;
male
Screened
at 3 days;
male
31

32

5-6
weeks;
male
30

Ukn

Muslim
First cousins

No
hospitalized at age of 5 weeks for episode of
gastroenteritis, lethargy, developed seizures

Petit mal seizures in mat. aunt and mat.
grandfather, migraine headaches in mother.
Brother died at 14 months after developing
seizures and liver failure
Yes (younger sibling case 30)

Yes, sister and male cousin (similar course)

Low
Elevated

No
vomiting, hypotonia, visual impairment,
persistent head and body shaking
Ukn
29

5 years 7
months;
male
5 months;
female
28

Ukn
No

No
history of lethargy and poor appetite
Ukn

215

Elpeleg et al. Eur J Pediatr. 1990
Jun;149(9):634-636.53

Pandya et al. J Inherit Metab Dis.
1991;14(5):685-690.52

Burlina et al. J Inherit Metab Dis.
1992;15(3):395-398.51

Partial NAGS deficiency
Liver biopsy: NAGS activity reduced to 40% of
control
Liver biopsy revealed NAGS activity
undetectable
6
755

24
850
>200

No
3-4 days;
male
27

Yes; first cousins
Taiwanese
No

oliguria, trembling, seizure, hypotonia, coma

285

Vockley et al. Biochem Med Metab Biol.
1992;47(1):38-46.50
Liver biopsy: NAGS activity reduced to 9.7%
of control

Guffon et al. J Inherit Metab Dis.
1995;18(1):61-65.17
Liver biopsy: NAGS activity <10% control
<1
1054

Partial NAGS deficiency
Liver biopsy: NAGS activity <50% control

Ukn

530

ND

2
1571

1186

No
confusion, combative behaviour

316
No
vomiting, hyperventilation, respiratory alkalosis

Ukn

4 days;
female
20 years;
male
26

25

Ukn
First cousins
Ukn
Yes; first cousins
Ukn

Ukn

525

Liver biopsy: NAGS activity <5% control

Morris et al.J Inherit Metab Dis.
1998;21(8):867-868.48
Hinnie et al. J Inherit Metab Dis.
1997;20(6):839-840.49
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Significant asterixis was present and gait assessment was
normal. Otherwise general examination was unremarkable.
The patient was admitted to hospital. Extensive laboratory
studies were all within normal limits. Magnetic resonance
imaging of head and full-spine were reviewed with expert neuroradiologists and deemed normal. Plasma ammonia was found to
be markedly elevated at 434 umol/L (15-55 umol/L). A blood gas
revealed a mild respiratory alkalosis. Continuous EEG
monitoring (Figure 3) demonstrated severe generalized
encephalopathy with associated triphasic waves suggesting
metabolic or hepatic etiology with no epileptiform activity.
The patient responded well to intravenous fluids, lactulose
and a relatively lower protein diet. Upon discharge plasma
ammonia levels decreased to 85 umol/L. A referral was made to
a genetics/metabolics specialist to further investigate an
underlying metabolic etiology.
A complete metabolic work-up revealed an elevated
glutamine level of 1062 mmol/L (109-750 mmol/L), normal
citrulline at 15 mmol/L (10-50 mmol/L), and normal urine amino
acids. Urine orotic acid level was normal. On molecular studies
OTC gene sequencing was normal (this was done as OTC
deficiency is the most common UCD and orotic acid can be
normal in OTC patients). Molecular sequencing of the NAGS
gene was performed and the patient was found to be a compound
heterozygote for E433G and IVS6+5 G > A, both novel
mutations. The intronic mutation involved a consensus base pair
located 5 bp downstream of an exon/intron boundary, in the
donor splice site of intron 6. A G>A substitution in this position
is expected to reduce efficiency of splicing of NAGS mRNA and
lead to decreased, but not absent, expression of NAGS from this
allele24. The residual NAGS expression from this allele likely
resulted in sufficient NAGS enzymatic activity to avoid neonatal
hyperammonemia, and may serve to explain a delayed onset in
adult life in our patient.
Mutation sequencing of NAGS was obtained in both parents.
The patient’s father was confirmed to be a carrier of the IVS6+5
G >A mutation, but interestingly, no mutation was identified in
the patient’s reported biological mother. Non-maternity, gonadal
mosaicism or a de novo mutation may explain the absence of the
E433G mutation in the mother.
Medical management of our case

A relatively low protein diet (around 1 gm/kg about <73
g/day) was commenced and our patient’s ammonia level was
maintained in the normal range. Initially he was also started on
sodium phenylbutyrate 200 mg/kg TID (4500 mg TID) and
citrulline 50mg/kg TID (1200 mg TID). Sodium phenylbutyrate
reduces ammonia production by creating an alternate pathway
for the excretion of nitrogen containing precursors while
citrulline also aids in nitrogen clearance and in maintaining the
arginine pool in proximal UCDs.
Carglumic acid

Our patient was eventually switched to carglumic acid 1200
mg TID and a more liberalized protein intake once the diagnosis
of NAGS deficiency was confirmed. The switch was made to
carglumic acid because of non-compliance with a low-protein
diet, intolerance to sodium phenylbutyrate and citrulline
(stomach distress and body odour) and the specificity of
7
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carglumic acid to NAGS deficiency. Carglumic acid activates
CPSI therefore leading to a reduction in ammonia levels.
Currently our patient’s ammonia levels are normal and range
from 29-35 umol/L.
Carglumic acid is much more expensive than sodium
phenylbutyrate (daily cost $1961.00 Canadian dollars for
carglumic acid vs. $8.46 for sodium phenylbutyrate at current
prices) however carglumic acid is the standard of care for
patients with NAGS deficiency despite the cost, as treatment
with scavengers and protein restriction are insufficient to prevent
breakthrough hyperammonemia which would cause resultant
increase in patient morbidity.25,26
Long-term management and morbidity

Our patient did eventually resume his work on the farm but
remains troubled with mild short term memory loss. His
behaviour has also shown a marked improvement. He has not
had a hyperammonemic crisis for the last two years. His
therapeutic course has been plotted (Figure 5).
Patients with UCD can present at any age and during
hyperammonemic crises mortality can be as high as 10%27. In
chronic management, avoidance of periods of stress is important.
Other neurologic sequelae of hyperammonemia may include
seizures and/or developmental delay. Evidence suggests that
virtually all survivors of a hyperammonemic coma are left with
developmental delay28-30. Cognitive impairment in adult-onset
presentations has been described even in asymptomatic OTCdeficient heterozygous women (learning disabilities and
attention deficit hyperactivity disorder)31,32. Although not
specific to NAGS deficiency a recent review by Gropman et al33
does suggest that there is a neurochemical basis for cognitive and
motor delay that may not only involve ammonia and glutamine
as neurotoxins, but also alterations in the levels of

neurotransmitters all leading to neuropathological changes. No
specific literature exists regarding documenting cognitive
deficits in adult-onset presentation of NAGS deficiency as it is a
very rare condition.
CONCLUSIONS

Plasma ammonia should be measured in all patients with an
unexplained encephalopathy including cyclical presentations to
identify potential underlying metabolic disorders. Electroencephalogram can be a clue with the presence of triphasic
waves indicating a metabolic encephalopathy. Hyperammonemia with a normal anion gap and normal serum glucose
should be investigated to rule out a urea cycle disorder. Our
illustrative case describes a rare presentation of a rare urea cycle
disorder. Management for these patients requires a
multidisciplinary approach including a dietician, social worker
and a genetic counsellor. Awareness of inborn errors of
metabolism presenting with neuro-psychiatric manifestations is
essential for all adult neurologists and psychiatrists. Genetic
counselling is an important component of UCDs management.
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